Exscien Corporation, a Mobile-based biotechnology firm that develops drugs to repair damage to mitochondrial DNA, will provide the first available treatment for diverse and common diseases, ranging from organ transplant to multi-organ system failure. The company is working on studies in the lung, stroke and cardiac model.
The startup company recently received a $3 million federal funding boost, winning a Phase II of the Small Business Technology Transfer National Institutes of Health grant with assistance from Alabama Launchpad, a program of the Economic Development Partnership of Alabama. Exscien is one of many companies that took advantage of writing assistance from Alabama Launchpad’s consultant, Jim Greenwood of Greenwood Consulting Group, Inc. (GCGI). The company also is one of six companies to receive $5,000 awards for accounting compliance.
Exscien’s Chief Executive Officer W.K. (Ker) Ferguson explained that the assistance of Alabama Launchpad and its programming support provided Exscien with overall guidance and insights into the preparation of its grant submissions, as well as direct, expert feedback on Exscien’s research and commercialization plans for the Phase II application.
“This support was invaluable and no doubt contributed to a perfect score of ’10’ on our Phase II application to the NIH and an award in excess of $3 million over two years,” Ferguson noted.
Learn more about Exscien by visiting our blog.